Fairvalue-Calculator Fairvalue-Calculator
EN DE

Enimmune Corporation (6564) Fair Value & Analysis

Healthcare · TW · Market cap 1.2B TWD

Price16.30 TWD
Fair Value6.23 TWD
Upside-61.8%
Quality95/100
Evidence: Low Range 4.67 TWD – 7.78 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Enimmune Corporation (6564) currently trades at 16.30 TWD, while our model-based Fair Value estimate is 6.23 TWD — implying the stock looks roughly 61.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, which is in pre-clinical stage for the treatment of Japanese encephalitis virus; EV71+CA16 bivalent vaccine, which is in research stage for the treatment of hand-foot-mouth disease caused by Coxsackie A virus and enterovirus 71; and Anti-RBD monoclonal antibody, a murine monoclonal antibody for the recognition of receptor binding domain of the SARS-CoV-2 spike protein. The company was founded in 2014 and is based in Taipei, Taiwan. Enimmune Corpor…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Enimmune Corporation (6564) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 6.23 TWD versus a price of 16.30 TWD — about −62% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6564?
Our 21-model fair value for Enimmune Corporation is 6.23 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 16.30 TWD.
What is the quality score of 6564?
Enimmune Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.